SK Chemicals collaborated with Janssen Korea to predict a change in the domestic anti-inflammatory analgesic’ultraset (ingredient name acetaminophen·trimadol hydrochloride)’ market.
On the 15th, SK Chemicals announced that it has signed a’domestic sales agreement’ with Janssen Korea for the’ultraset’ family of anti-inflammatory analgesics. There are four types of contracts: ▲Ultraset ▲Ultrasetsemi tablet ▲Ultraset RSeobang ▲UltrasetYRSemi Seobang.
This domestic sales agreement between SK Chemicals and Janssen Korea is the second following the dementia treatment’Reminil (ingredient name galantamine hydrobromide)’ in 2019. In charge. Janssen Korea is in charge of production. However, the two companies did not disclose the duration of this domestic sales agreement.
Ultraset, developed in 2002, is a combination of acetaminophen and trimadol hydrochloride, and is used for moderate to severe acute and chronic pain.
In recent years, the ultraset market is fiercely competitive with generic products being released. Since the expiration of the Ultraset patent in 2008, 126 generic products have been released in Korea, and a total of 249 products have been released so far, including generics of the Ultraset family, and are competing.
According to the pharmaceutical market research institute IQVIA, the domestic Ultraset market was totaled 60.2 billion won until the third quarter of last year, and Ultraset recorded 18.3 billion won in sales in Korea until the same quarter last year.
It is interpreted that defense against the generic offensive is necessary. In the midst of this, Janssen Korea and Daewoong Pharm conducted domestic sales cooperation with Ultraset from 2009 to 2017, and recently took SK Chemicals as a new partner.
Janssen Korea is expecting the market share of Ultraset to expand once more with this agreement with SK Chemicals.
SK Chemicals is co-promoting its own osteoarthritis treatment drug’Joins (ingredient name: Wiryeongseon, brace roots, hagocho 30% ethanol dry extract)’ and’Simbalta’ (ingredient name duloxetine hydrochloride), an antidepressant and osteoarthritis pain treatment from Lily Korea. As such, the portfolio of analgesic anti-inflammatory drugs has been strengthened.
“Through this agreement, our analgesic anti-inflammatory portfolio has been further strengthened,” said Kim Jeong-hoon, head of SK Chemicals Pharma Planning Office.